Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.67 |
| ▸ | FLT1 | P17948 | 4/20 | 0.67 |
| ▸ | KIT | P10721 | 3/20 | 0.67 |
| ▸ | ABL1 | P00519 | 2/20 | 0.67 |
| ▸ | CSF1R | P07333 | 2/20 | 0.67 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.67 |
| ▸ | FLT4 | P35916 | 2/20 | 0.67 |
| ▸ | EGFR | P00533 | 1/20 | 0.67 |
| ▸ | IGF1R | P08069 | 1/20 | 0.60 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.60 |
| ▸ | TEK | Q02763 | 1/20 | 0.60 |
| ▸ | BRAF | P15056 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.57 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4978310 | 0.85 | KDR (0.71) | KDRFLT1KITABL1CSF1R | |
| SCHEMBL4982146 | 0.85 | KDR (0.71) | KDRFLT1KITABL1CSF1R | |
| SCHEMBL4977683 | 0.84 | KDR (0.71) | KDRFLT1KITABL1CSF1R | |
| SCHEMBL4976779 | 0.83 | KDR (0.71) | KDRFLT1KITABL1CSF1R | |
| SCHEMBL4981491 | 0.83 | KDR (0.72) | KDRFLT1KITABL1CSF1R | |
| SCHEMBL4982167 | 0.83 | KDR (0.71) | KDRFLT1KITABL1CSF1R | |
| SCHEMBL4976546 | 0.83 | KDR (0.67) | KDRFLT1KITABL1CSF1R | |
| SCHEMBL4977490 | 0.83 | KDR (0.80) | KDRFLT1KITABL1CSF1R | |
| SCHEMBL27485937 | 0.82 | KDR (0.70) | KDRFLT1KITABL1CSF1R | |
| SCHEMBL4983660 | 0.82 | KDR (0.66) | KDRFLT1KITABL1CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040198782-A1 | N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ (CH) | 2004-10-07 | — | — | US | claimed |
| US-20080085902-A1 | Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent | BOLD GUIDO | 2008-04-10 | — | — | US | disclosed |
| US-20060074112-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ | 2006-04-06 | — | — | US | disclosed |
| US-7002022-B2 | N-Aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF | NOVARTIS AG (CH) | 2006-02-21 | — | — | US | disclosed |
| US-20040198782-A1 | N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ (CH) | 2004-10-07 | — | — | US | disclosed |
| US-6448277-B2 | ANTITUOR AGENTS, ANTICARCINOGENIC AGENTS | NOVARTIS AG (CH) | 2002-09-10 | — | — | US | disclosed |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085902-A1 | Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent | VEGFA, FLT1, FLT4 | KDR 4/4885FLT1 2/4885KIT 95/4885 |
| US-20060074112-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | NR2E3, AXL, FLT1 | KDR 6/4885FLT1 3/4885KIT 1240/4885 |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, KDR | KDR 3/4885FLT1 6/4885KIT 1055/4885 |
| US-20040198782-A1 | N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, NR2E3 | KDR 4/4885FLT1 6/4885KIT 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.